PT3616696T - Composição farmacêutica administrável oralmente contendo enzalutamida - Google Patents

Composição farmacêutica administrável oralmente contendo enzalutamida

Info

Publication number
PT3616696T
PT3616696T PT187914866T PT18791486T PT3616696T PT 3616696 T PT3616696 T PT 3616696T PT 187914866 T PT187914866 T PT 187914866T PT 18791486 T PT18791486 T PT 18791486T PT 3616696 T PT3616696 T PT 3616696T
Authority
PT
Portugal
Prior art keywords
enzalutamide
pharmaceutical composition
orally administrable
containing pharmaceutical
administrable
Prior art date
Application number
PT187914866T
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT3616696T publication Critical patent/PT3616696T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT187914866T 2017-04-28 2018-04-27 Composição farmacêutica administrável oralmente contendo enzalutamida PT3616696T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017090300 2017-04-28

Publications (1)

Publication Number Publication Date
PT3616696T true PT3616696T (pt) 2025-04-03

Family

ID=63920425

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187914866T PT3616696T (pt) 2017-04-28 2018-04-27 Composição farmacêutica administrável oralmente contendo enzalutamida

Country Status (13)

Country Link
US (1) US12036315B2 (pt)
EP (1) EP3616696B1 (pt)
JP (1) JP7172997B2 (pt)
KR (1) KR102684756B1 (pt)
CN (1) CN110573153B (pt)
AU (1) AU2018256998B2 (pt)
CA (1) CA3060366A1 (pt)
ES (1) ES3018265T3 (pt)
MX (1) MX394857B (pt)
PL (1) PL3616696T3 (pt)
PT (1) PT3616696T (pt)
RU (1) RU2019138248A (pt)
WO (1) WO2018199282A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
SG11202106839XA (en) 2018-12-27 2021-07-29 Asahi Chemical Ind Cellulose powder, use thereof, and tablets
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤
WO2021240206A1 (en) * 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
JP7414668B2 (ja) 2020-08-28 2024-01-16 信越化学工業株式会社 ポリビニルアルコール含有造粒物及び固形製剤
KR20230098278A (ko) * 2020-10-28 2023-07-03 메르크 파텐트 게엠베하 난용성 활성 약학 성분의 용해도를 향상시키기 위한 약학 조성물 및 방법
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
JPH10316576A (ja) 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
RU2205191C1 (ru) 2001-12-27 2003-05-27 Институт синтетических полимерных материалов им. Н.С. Ениколопова РАН Способ получения аморфизованного поливинилового спирта
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CN102137663B (zh) * 2008-09-12 2016-09-28 第一三共健康事业株式会社 抑制变色的稳定的药物制剂
DK2538785T3 (en) 2010-02-24 2018-05-22 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
AU2012230733B2 (en) * 2011-03-23 2016-10-20 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
JP6404217B2 (ja) * 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
KR20150053963A (ko) 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP6274641B2 (ja) 2013-09-13 2018-02-07 独立行政法人 国立印刷局 偽造防止媒体及びその作製方法
JP6133445B2 (ja) * 2014-01-30 2017-05-24 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有4環性化合物的製劑
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
JP6403615B2 (ja) * 2015-03-18 2018-10-10 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法
JP2016056208A (ja) * 2016-01-15 2016-04-21 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法

Also Published As

Publication number Publication date
RU2019138248A3 (pt) 2021-07-21
KR20190137920A (ko) 2019-12-11
CN110573153B (zh) 2023-04-04
AU2018256998A1 (en) 2019-12-05
EP3616696A1 (en) 2020-03-04
JP7172997B2 (ja) 2022-11-16
US20200146977A1 (en) 2020-05-14
PL3616696T3 (pl) 2025-05-05
AU2018256998B2 (en) 2023-11-09
WO2018199282A1 (ja) 2018-11-01
US12036315B2 (en) 2024-07-16
EP3616696A4 (en) 2021-01-27
ES3018265T3 (en) 2025-05-14
MX2019012757A (es) 2019-12-16
JPWO2018199282A1 (ja) 2020-03-12
CA3060366A1 (en) 2018-11-01
EP3616696B1 (en) 2025-03-05
MX394857B (es) 2025-03-24
RU2019138248A (ru) 2021-05-28
KR102684756B1 (ko) 2024-07-15
CN110573153A (zh) 2019-12-13

Similar Documents

Publication Publication Date Title
ZA202001037B (en) Novel orally administrable formulation
ZA201805802B (en) Orally administrable composition
PT3616696T (pt) Composição farmacêutica administrável oralmente contendo enzalutamida
IL271657A (en) medical preparation
IL271986A (en) pharmaceutical preparation
GB201712159D0 (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
PL3583943T3 (pl) Kompozycja farmaceutyczna
GB201804548D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
GB201705306D0 (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
PL3646867T3 (pl) Kompozycja farmaceutyczna
GB201808571D0 (en) Pharmaceutical compositions
GB201808567D0 (en) Pharmaceutical compositions
ZA202000014B (en) Pharmaceutical compositions
IL271513A (en) Innovative pharmaceutical composition
IL272044A (en) Pharmacy preparations
IL272428A (en) pharmaceutical preparations
GB201809030D0 (en) Novel pharmaceutical uses
GB201715404D0 (en) Pharmaceutical compositions
GB201710114D0 (en) Pharmaceutical compositions